Core Viewpoint - The company reported a strong interim performance for the six months ending June 30, 2025, with significant revenue growth driven by its innovative drug business and strategic partnerships [1][2] Financial Performance - The company achieved revenue of 3.585 billion RMB, a year-on-year increase of 15.1% [1] - Net profit attributable to shareholders reached 604 million RMB, up 32.2% year-on-year [1] - Adjusted net profit was 651 million RMB, reflecting a growth of 21.1% year-on-year [1] - Research and development (R&D) expenses totaled 1.028 billion RMB, a substantial increase of 68%, representing 28.7% of total revenue [1] Business Segments - The innovative drug business contributed 2.776 billion RMB, accounting for 77.4% of total revenue, with a year-on-year growth of 26% [1] - Neuroscience revenue was 1.249 billion RMB, showing a robust increase of 37.3% year-on-year [1] - Oncology revenue reached 874 million RMB, marking a significant growth of 41.1% year-on-year [1] - Autoimmunity revenue remained stable at 878 million RMB, with a year-on-year increase of 3.3% [1] Strategic Developments - The company made important breakthroughs in product pipeline and commercialization, with the approval of innovative drugs such as Kewike (Dareliberine Hydrochloride Tablets) and Enzeshou (Suvorexant Injection) in China [1] - Strategic collaborations were established with international pharmaceutical companies like AbbVie, NextCure, and Idorsia, focusing on ADC, tri-antibody, and central nervous system drug development [2] - The company plans to continue focusing on core areas such as neurology, oncology, autoimmunity, and anti-infection to enhance its innovative drug R&D and commercialization capabilities [2]
先声药业上半年营收35.85亿元 创新药收入同比增长26%